non-small cell lung cancer
Conditions
Interventions
None listed
Sponsors
Kitagawa Hiroshi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: -Stage I-III (AJCC v8 or v9) at initial NSCLC diagnosis -Aged 18 years or older at first diagnosis of NSCLC (20+ years of age in Taiwan)
Exclusion criteria
Exclusion criteria: -Stage III NSCLC patients not amenable to curative intent treatment -NSCLC is not the primary cancer diagnosis -Participation in any interventional clinical trial for initial treatment of Stage I-III NSCLC -History of another primary malignancy except for malignancy treated with curative intent with no known active disease more than 2 years before the diagnosis of NSCLC. Exceptions include adequately resected non-melanoma skin cancer and curatively treated in situ disease. Patients who have received RT with overlapping fields (e.g., cured breast cancer) should be excluded -Any presence of small cell and mixed small-cell and non-small cell histology -A positive pregnancy status at the time of diagnosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| -Treatment patterns -Duration of treatment -Time from diagnosis to treatment initiation -Time to treatment discontinuation -Reasons for treatment discontinuation | — |
Secondary
| Measure | Time frame |
|---|---|
| -Subsequent treatment patterns -Adverse events -Biomarker testing -Real-world overall survival (OS) -Real-world progression free survival (rwPFS) -Real-world event free survival (rwEFS) -Real-world disease free survival (rwDFS) -Real-world time to distant metastasis (TTDM) | — |
Countries
Brazil, Canada, Greece, Israel, Japan, KSA, Kuwait, Qatar, Singapore, Switzerland, UAE, United States
Contacts
Public ContactYuko Hayashi
AstraZeneca K.K.
Outcome results
None listed